Acacia Research Corp. ACTG
Pretty much the entirety of 2017 has been some tough sledding for ACTG, which was in an overall downtrend since last winter when it was trading at more than twice its current value.
That all seemed to change around midway through last month, as the stock has managed to establish a good rebound effort for several sessions. In the premarket the stock has broken previous resistance which coincided with the 50DMA (3.63) and could make a move to fill that gao we’ve pointed out on the chart below.
We’ll put the stock on watch in the days and weeks ahead as we kick off this holiday-shortened trading week.
Insmed, Inc. INSM
After posting key data reflecting positive top-line results in its Phase III lung disease treatment study, INSM has exploded into the blue sky this morning. The stock has rapidly gained more than twice its value in premarket trading, and whenever we come across a situation like this, we begin to look for the options contracts that could give us the best opportunity for rapid gains.
We think that the INSM 09/15 $27-30 Calls could stand to see some nice activity if the stock continues the blue-sky breakout we’ve witnessed so far.
ONCI, VDRM, MYDX, BSTG, PTN, BSRX, BLPH